This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guo, T. Articles by Antonescu, C. R. Search for Related Content PubMed PubMed Citation Articles by Guo, T. Articles by Antonescu, C. R.

Sorafenib Inhibits the Imatinib-Resistant KIT^T670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor

Authors' Affiliations: Departments of ¹ Pathology, ² Medicine, and ³ Surgery, Memorial Sloan-Kettering Cancer Center; ⁴ Developmental Biology Program and ⁵ Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, New York, New York

Requests for reprints: Cristina R. Antonescu, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Phone: 212-639-5721; Fax: 212-717-3203; E-mail: antonesc{at}mskcc.org.

Purpose: Resistance is commonly acquired in patients with metastatic gastrointestinal stromal tumor who are treated with imatinib mesylate, often due to the development of secondary mutations in the KIT kinase domain. We sought to investigate the efficacy of second-line tyrosine kinase inhibitors, such as sorafenib, dasatinib, and nilotinib, against the commonly observed imatinib-resistant KIT mutations (KIT^V654A, KIT^T670I, KIT^D820Y, and KIT^N822K) expressed in the Ba/F3 cellular system.

Experimental Design: In vitro drug screening of stable Ba/F3 KIT mutants recapitulating the genotype of imatinib-resistant patients harboring primary and secondary KIT mutations was investigated. Comparison was made to imatinib-sensitive Ba/F3 KIT mutant cells as well as Ba/F3 cells expressing only secondary KIT mutations. The efficacy of drug treatment was evaluated by proliferation and apoptosis assays, in addition to biochemical inhibition of KIT activation.

Results: Sorafenib was potent against all imatinib-resistant Ba/F3 KIT double mutants tested, including the gatekeeper secondary mutation KIT^{WK557-8del/T670I}, which was resistant to other kinase inhibitors. Although all three drugs tested decreased cell proliferation and inhibited KIT activation against exon 13 (KIT^{V560del/V654A}) and exon 17 (KIT^V559D/D820Y) double mutants, nilotinib did so at lower concentrations.

Conclusions: Our results emphasize the need for tailored salvage therapy in imatinib-refractory gastrointestinal stromal tumors according to individual molecular mechanisms of resistance. The Ba/F3 KIT^{WK557-8del/T670I} cells were sensitive only to sorafenib inhibition, whereas nilotinib was more potent on imatinib-resistant KIT^{V560del/V654A} and KIT^V559D/D820Y mutant cells than dasatinib and sorafenib.

This article has been cited by other articles:

				M. C. Heinrich, R. G. Maki, C. L. Corless, C. R. Antonescu, A. Harlow, D. Griffith, A. Town, A. Mckinley, W.-B. Ou, J. A. Fletcher, et al. Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor J. Clin. Oncol., November 20, 2008; 26(33): 5352 - 5359. [Abstract] [Full Text] [PDF]

				S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol. Cancer Ther., October 1, 2008; 7(10): 3129 - 3140. [Abstract] [Full Text] [PDF]

				C. Nishioka, T. Ikezoe, J. Yang, A. Miwa, T. Tasaka, Y. Kuwayama, K. Togitani, H. P. Koeffler, and A. Yokoyama Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo Blood, May 15, 2008; 111(10): 5086 - 5092. [Abstract] [Full Text] [PDF]